Evolus(EOLS) - 2025 Q4 - Annual Report

Financial Performance - The company has incurred significant losses since inception, which may continue to adversely affect the market price of its common stock and ability to raise additional capital[14] - The terms of the Medytox Settlement Agreements will continue to reduce profitability[17] - The company may require additional financing for future operations, and failure to secure capital could force delays or reductions in operations[17] Competition and Market Challenges - The products Jeuveau and Evolysse™ face significant competition, and failure to compete effectively may hinder market share and expansion[14] - The company faces significant competition for its products, including Jeuveau and Evolysse™, which may hinder market share and expansion efforts[14] Consumer Spending and Economic Sensitivity - The company relies on consumer discretionary spending, which is sensitive to global economic conditions, potentially impacting sales[14] - The company's products rely on consumer discretionary spending, which is sensitive to global economic conditions, potentially impacting sales[14] Regulatory Approval and Compliance - Regulatory approval for the Evolysse™ product line in the United States is critical, and failure to maintain or obtain such approval could negatively affect sales[17] - The company is dependent on Symatese S.A.S. for regulatory approval of the Evolysse™ product line in the U.S., and failure to maintain or obtain approval could negatively affect sales[17] - The company must obtain additional regulatory approvals to expand product indications, which may be costly and not guaranteed[17] - The company is subject to extensive government regulation, which may result in delays or additional expenses in obtaining regulatory approvals[17] - The company is subject to extensive government regulation, which may result in delays or additional expenses related to regulatory compliance[17] Intellectual Property and Operational Risks - Third-party claims of intellectual property infringement may disrupt commercialization efforts and supply chains[17] - The company’s reliance on digital technology means that information system failures or cybersecurity incidents could significantly impact operations[17] - The company’s business and operations could suffer from information system failures or cybersecurity incidents[17] Licensing and Partnerships - The company relies on licensing agreements with Daewoong Pharmaceutical and Symatese, and loss of these rights could adversely affect business[17]